In a new milestone in Iran’s medical and pharmaceutical sector, the National Institute of Genetic Engineering and Biotechnology, established under the supervision of the Iranian Ministry of Science, Research and Technology, announced introducing a groundbreaking anti-cancer vaccine this summer which is expected to enhance the patients’ treatment accessibility.
The Institute’s head Javad Mohammadi noted that designed to target various types of cancer, the vaccine should “significantly reduce reliance on imported medications” and – through domestic research and technological advancements – and “reinforce efforts to develop innovative healthcare solutions.”
As reported by Mehr News Agency, Iran’s knowledge-based companies based at the Genetic Research Institute that has advanced this technology “are currently capable of meeting 70% of national demand,” but “will soon be able to supply the country’s full requirements.”
